Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers

Advances in Experimental Medicine and Biology

Volumn 586, Issue , 2006, Pages 381-390

  Calano, Sarah J ^a   Shih, Pei An B ^a   Liu, Chau Ching ^a   Kao, Amy H ^a   Navratil, Jeannine S ^a   Manzi, Susan ^a   Ahearn, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934440061     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34134-X_25     Document Type: Conference Paper

References (44)

1. C. Hohan, S.K. Datta, Lupus. Key pathogenic mechanisms and contributing factors, Clin Immunol Immunopathol 77:209-220 (1996).
2. P.H. Schur, Complement and lupus erythematosus, Arthritis Rheum 25:793-798 (1982).
3. P.A. Gatenby, The role of complement in the aetiopathogenesis of systemic lupus erythematosus, Autoimmunity 11:61-66 (1991).
4. J.S. Navratil, J.M. Ahearn, Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus, Curr Rheumatol Rep 2:32-38 (2001).
5. M.L. Barilla-LaBarca, J.P. Atkinson. Rheumatic syndromes associated with complement deficiency, Curr Opin Rheumatol 15:55-60 (2003).
6. A.P. Manderson, M. Botto, M.J. Walport, The role of complement in the development of systemic lupus erythematosus, Annu Rev Immunol 22:431-456 (2004).
7. M.C. Carroll, The role of complement and complement receptors in induction and regulation of immunity, Annu Rev Immunol 16:545-568 (1998).
8. R. Barrington, M. Zhang, M. Fischer, M.C. Carroll, The role of complement in inflammation and adaptive immunity, Immunol Rev 180:5-15 (2001).
9. P.H. Schur, J. Sandson, Immunological factors and clinical activity in systemic lupus erythematosus, N Engl J Med 278:533-538 (1968).
10. J.H. Vaughan, T.B. Bayles, C.B. Favour, The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone (ACTH) therapy in lupus erythematosus disseminatus, J Lab Clin Med 37:698-702 (1951).
11. W. Lloyd, P.H. Schur, Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE), Medicine 60:208-217 (1981).
12. R.M. Valentijn, H. van Overhagen, H.M. Hazevoet, J. Hermans, A. Cats, M.R. Daha, et al., The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus, Arthritis Rheum 28:904-913 (1985).
13. D.M. Ricker, L.A. Hebert, R. Rohde, D.D. Sedmak, E.J. Lewis, J.D. Clough, et al., Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels, Am J Kidney Dis 19:678-685 (1991).
14. L. Milis, B.A. Pussell, V. Timmermans, J.A. Charlesworth, C.A. Morris, The value of complement measurements in the assessment of lupus activity, Aust NZ J Med 22:338-344 (1992).
15. J.S. Cameron, M.H. Lessof, C.S. Ogg, B.D. Williams, D.G. Williams, Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations, DNA-binding capacity, and precipitating anti-DNA antibody, Clin Exp Immunol 25:418-427 (1976).
16. A.J. Swaak, J. Groenwold, W. Bronsveld, Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus, Ann Rheum Dis 45:359-366 (1986).
17. C-K. Ting, K-H Hsieh, A long term immunological study of childhood onset systemic lupus erythematosus, Ann Rheum Dis 51:45-51 (1992).
18. C.K. Abrass, K.M. Nies, J.S. Louie, W.A. Border, R.J. Glassock, Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus, Arthritis Rheum 23:273-282 (1980).
19. W.J.W. Morrow, D.A. Isenberg, A. Todd-Porkropek, H.F. Parry, M.L. Snaith, Useful laboratory measurements in the management of systemic lupus erythematosus, Q J Med 202:125-138 (1982).
20. J.M. Esdaile, M. Abrahamowicz, L. Joseph, T. MacKenzie, Y. Li, D. Danoff, Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail, Arthritis Rheum 39:370-378 (1996).
21. J.M. Esdaile, L. Joseph, M. Abrahamowicz, D. Danoff, A.E. Clarke. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 23:1891-1896 (1996).
22. L.D. Kerr, B.R. Adelsberg, H. Spiera, Complement activation in systemic lupus erythematosus: a marker of inflammation, J Rheumatol 13:313-319 (1986).
23. E. Rother, B. Lang, R. Coldewey, K. Hartung, H.H. Peter, Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus, Clin Rheumatol 12:31-35 (1993).
24. H.M. Belmont, P. Hopkins, H.S. Edelson, H.B. Kaplan, R. Ludewig, G. Weissmann, et al., Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease, Arthritis Rheum 29:1085-1089 (1996).
25. S. Manzi, J.E. Rairie, A.B. Carpenter, R.H. Kelly, S.P. Jagarlapudi, S.M. Sereika, et al., Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity, Arthritis Rheum 39:1178-1188 (1996).
26. Y.Y. Chiu, R.M. Nisihara, R. Wurzner, M. Kirschfink, I.J. do Messias-Reason, sC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients, J Investig Allergy Clin Immunol 8:239-244 (1998).
27. P. Hopkins, H.M. Belmont, J.P. Buyon, M. Philips, G. Weissmann, S.B. Abramson, Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis, Arthritis Rheum 31:632-641 (1988).
28. G. Sturfelt, L. Jonasson, A.G. Sjoholm, Sequential studies of complement activation in systemic lupus erythematosus, Scand J Rheumatol 14:184-196 (1985).
29. J.A. Sliwinski, N.J. Zvaifler, Decreased synthesis of the third component (C3) in hypocomplementemic systemic lupus erythematosus, Clin Exp Immunol 11:21-29 (1972).
30. F.B. Waldo, C.D. West, Quantitation of (C1INH)2-C1r-C1s complexes in glomerulonephritis as an indicator of C1 activation, Clin Immunol Immunopathol 42:239-249 (1987).
31. G. Senaldi, V.A. Makinde, D. Vergani, D.A. Isenberg, Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus, Ann Rheum Dis 47:913-917 (1988).
32. L.H. Perrin, P.H. Lambert, P.A. Miescher, Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephtitis, J Clin Invest 56:165 (1975).
33. P. Horak, V. Scudla, Z. Hermanova, Z. Pospisil, L. Faltynek, M. Budikova, et al., Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus, Clin Rheumatol 20:337-344 (2001).
34. G. Sturfelt, A.G. Sjoholm, Complement components, complement activation, and acute phase response in systemic lupus erythematosus, Int Arch Allerg Appl Immunol 75:75-83 (1984).
35. C.A. Alper, F.S. Rosen, Studies of the in vivo behavior of human C3 in normal subjects and patients. J Clin Invest 46:2021-2034 (1967).
36. L.G. Hunsicker, S. Ruddy, C.B. Carpenter, P.H. Schur, J.P. Merrill, H.J. Muller-Eberhard, et al., Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med 287:835-840 (1972).
37. J.A. Charlesworth, P.W. Peake, J. Golding, J.D. Mackie, Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus, Ann Rheum Dis 48:153-159 (1989).
38. C.A. Tieley, D.G. Romans, M.C. Crookston, Localization of Chido and Rodgers determinants to the C4d fragment of human C4, Nature 276:713-735 (1978).
39. J.P. Atkinson, A.C. Chan, D.R. Karp, C.C. Killion, R. Brown, D. Spinella, et al., Origin of the fourth component of complement related Chido and Rodgers blood group antigens, Complement 5:65-76 (1998).
40. R.E. Rosenfield, Jagathambal, Antigenic determinants of C3 and C4 complement components on washed erythrocytes from normal persons, Transfusion 18:517-523 (1977).
41. J. Freedman, M. Ho, C. Barefoot, Red blood cell-bound C3d in selected hospital patients, Transfusion 22:515-520 (1982).
42. G.D. Ross, W.J. Yount, M.J. Walport, J.B. Winfield, C.J. Parker, C.R. Fuller, et al., Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation, J Immunol 135:2005-2014 (1985).
43. S. Manzi, J.S. Navratil, M.J. Ruffing, C-C. Liu, N. Danchenko, S.E. Nilson, et al., Measurement of erythrocyte C4d and complement receptor 1 in the diagnosis of systemic lupus erythematosus, Arthritis Rheum 50:3596-3604 (2004).
44. C-C. Liu, S. Manzi, A.H. Kao, J.S. Navratil, M.R. Ruffing, and J.M. Ahearn, Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus, Arthri Rheum 52:3087-3099 (2005).